Analysis to Identify Biomarkers Associated With ADPKD

Overview

About this study

The purpose of this study is to collect biological samples (whole blood and saliva) to develop and validate a genotype assay for  Autosomal Dominant Polycystic Kidney Disease (ADPKD). Also, to determine the associations between genotype and ADPKD severity and/or progression, and to collect biological samples (blood and urine) to develop exploratory biomarker assays for potential correlation with ADPKD disease severity and/or progression.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or Female patients, 18 years of age and above.
  • Diagnosis of ADPKD (ICD9 753.13 / 753.12 or ICD10 Q61.2 / Q61.3).

Exclusion Criteria: 

  • Unable to provide informed consent.
  • Prior renal transplant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/8/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Fouad Chebib, M.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available